News

Published on 18 Nov 2021 on Zacks via Yahoo Finance

Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote


Article preview image

Biogen BIIB and its Japan-based partner Eisai announced that they received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to their marketing authorization application for their Alzheimer’s disease (AD) drug, aducanumab, in Europe.

The CHMP’s negative trend vote was based on an oral explanation from Biogen in a meeting held earlier this month. Although the CHMP will provide its formal opinion in December, it is expected that it will maintain its stance and will recommend against the drug’s approval. Meanwhile, Biogen plans to engage in discussions with the EMA and the CHMP for resolving the issues that led to a negative trend vote.

We note that Biogen had a hard time getting approval for the drug in the United States as well. After much controversy, the FDA granted accelerated approval to aducanumab in June, largely based on its ability to remove beta amyloid seen in late-stage studies. However, it is still uncertain whether the reduction in beta amyloid leads to improvement in cognition. The drug is marketd as Aduhelm in the United States. Aduhelm’s FDA approval, despite an FDA advisory committee voting against it, faced a lot of criticism, due to the drug’s mixed efficacy results. The FDA approval is also for patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia but not for patients with earlier or later stages of the disease.

NASDAQ.BIIB price evolution
NYSE.LLY price evolution
NASDAQ.SAVA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

Biogen BIIB and partner Eisai recently announced that the European Medicines Agency’s (EMA) Commi...

Zacks via Yahoo Finance 26 Mar 2024

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

Laboratory Corporation of America Holdings, Inc. or Labcorp LH recently launched a new blood test...

Zacks via Yahoo Finance 25 Mar 2024

Dyne Therapeutics appoints John Cox as new CEO

Dyne Therapeutics appoints John Cox as new CEO

Investing.com 25 Mar 2024

EU delays decision on Eisai-Biogen Alzheimer’s drug (OTCMKTS:ESALF)

The decision on the marketing authorization application for Alzheimer's therapy Leqembi has been...

Seeking Alpha 22 Mar 2024

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2023 Earnings Call Transcript

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2023 Earnings Call Transcript March 21, 2024 Hyperfine, Inc. bea...

Insider Monkey via Yahoo Finance 22 Mar 2024

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

It was a busy week for the biotech sector with lots of study data readouts and regulatory approva...

Zacks via Yahoo Finance 21 Mar 2024

Hedge Funds and Insiders Are Buying These 10 Stocks

In this article, we will take a detailed look at Hedge Funds and Insiders Are Buying These 10 Sto...

Insider Monkey via Yahoo Finance 21 Mar 2024

Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared t...

Zacks via Yahoo Finance 18 Mar 2024

Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares hav...

Zacks via Yahoo Finance 15 Mar 2024

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

It is estimated by medical professionals that someone develops some form of dementia every three...

247wallst.com 15 Mar 2024